Head-to-Head: which chemo works better for HER2-Negative breast cancer?
NCT ID NCT03048942
First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time
Summary
This trial compares two chemotherapy drugs—cabazitaxel given every three weeks versus paclitaxel given weekly—as a first treatment for HER2-negative metastatic breast cancer. About 90 to 160 participants receive 18 weeks of one of the two drugs. The main goal is to see which drug delays cancer growth longer. Researchers also track tumor shrinkage and overall response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- two chemotherapy drugs: cabazitaxel (given every 3 weeks) and paclitaxel (given weekly)
- What this could lead to
- If cabazitaxel works better than paclitaxel, it could offer a new first-line chemotherapy option for people with HER2-negative metastatic breast cancer.
- What could go wrong
- This is a phase 2 pilot study with a relatively small number of participants, so results may not be definitive. Both drugs have significant side effects, and cabazitaxel may not prove superior.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2 NEGATIVE METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Blackpool Victoria Hospital
Blackpool, United Kingdom
-
Bristol Haematology and Oncology Centre, Horfield Road
Bristol, BS2 8ED, United Kingdom
-
City Hospital, Nottingham
Nottingham, United Kingdom
-
Derriford Hospital
Plymouth, United Kingdom
-
Freeman Hospital
Newcastle, United Kingdom
-
Guy's Hospital
London, United Kingdom
-
Imperial Healthcare NHS Trust
London, W6 8RF, United Kingdom
-
Musgrove Park Hospital
Taunton, United Kingdom
-
Royal Cornwall and Treliske
Truro, United Kingdom
-
Royal Devon and Exeter Hospital
Exeter, United Kingdom
-
Royal United Hospital
Bath, United Kingdom
-
Velindre Cancer Centre
Cardiff, United Kingdom
-
Worcestershire Acute Hospitals NHS Trust
Worcester, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.